PT-141 (Bremelanotide)

PT-141 (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II, engineered by Palatin Technologies to retain the sexual-arousal properties mediated by MC3R/MC4R while minimizing the melanogenic (tanning) effects of MC1R agonism. Its cyclic structure — formed by a lactam bridge between aspartic acid and lysine residues — provides metabolic stability and receptor selectivity.

The mechanism is centrally mediated through hypothalamic melanocortin pathways, making PT-141 fundamentally different from PDE5 inhibitors (sildenafil, tadalafil) that act peripherally on vascular smooth muscle. MC4R activation in the paraventricular nucleus (PVN) stimulates oxytocinergic neurons projecting to the spinal cord, activating sacral parasympathetic centers that control genital blood flow and arousal responses. Simultaneously, MC4R activation in the medial preoptic area (MPOA) triggers dopamine release in the mesolimbic reward pathway, promoting sexual motivation and subjective desire — the "wanting" component distinct from the physical arousal mechanism of PDE5 inhibitors.

The MC3R component contributes to reward processing and arousal state regulation through its own dopaminergic modulation. This dual MC3R/MC4R agonism produces both physiological arousal (MC4R-oxytocinergic-parasympathetic pathway) and psychological desire (MC4R/MC3R-dopaminergic-reward pathway). The 2.7-hour plasma half-life belies a 12–24 hour duration of clinical effect — a pattern explained by sustained central MC4R signaling in hypothalamic circuits long after systemic peptide clearance. This effect-duration paradox is characteristic of several neuroactive peptides where rapid receptor engagement triggers downstream signaling cascades that outlast plasma presence.

PT-141 was discovered serendipitously during Melanotan II tanning research at the University of Arizona in the 1990s, when male study subjects unexpectedly reported spontaneous erections — a side effect traced to MC4R activation in hypothalamic sexual-arousal pathways. Palatin Technologies isolated this mechanism, removed the MC1R-mediated tanning component via structural modification (removing a C-terminal carboxyl group), and developed PT-141 (bremelanotide) as a targeted sexual-desire therapeutic.

Phase 3 RECONNECT trials (n=1,247 premenopausal women with hypoactive sexual desire disorder) demonstrated statistically significant improvements in sexual desire scores and reductions in desire-related distress versus placebo. The FDA approved bremelanotide as Vyleesi in June 2019 — making it the first and only FDA-approved centrally acting medication for sexual desire disorder. Phase 2 studies in male erectile dysfunction showed pro-erectile effects independent of PDE5 inhibition, including efficacy in PDE5-inhibitor non-responders, though this indication has not progressed to Phase 3 as of 2026.

Store lyophilized PT-141 at -20°C in a light-protected, desiccated environment. The cyclic lactam-bridged structure provides significant metabolic stability — a key advantage over linear melanocortin analogues. Stability exceeds 24 months under optimal storage conditions.

After reconstitution with bacteriostatic water, PT-141 should be stored at 2–8°C and used within 21 days. Research protocols recommend a concentration of 1 mg/ml for precise dosing at the FDA-established 1.75 mg level. The on-demand nature of PT-141 research (rather than daily administration) means a single 10mg vial typically supports 5–10 research sessions, well within the 21-day stability window. The peptide should not be frozen after reconstitution. Nausea occurs in approximately 40% of administrations due to MC4R expression in brainstem emetic centers — this is a direct receptor-mediated effect, not a contaminant signal, and typically diminishes with repeated use.